Drugs Made In America Acquisition Corp. Rights Price & Performance (DMAAR)

NorthStrive Biosciences, a subsidiary of PMGC Holdings, has amended its licensing agreement with MOA Life Plus Co. to cover animal health applications, including feed additives. This move positions the company to tap into the U.S. animal health market, valued at $12.65 billion in 2024, with strong growth projected through 2030.1

Walgreens Boots Alliance has entered a definitive agreement to be acquired by Sycamore Partners. Shareholders will receive $11.45 per share in cash, with additional potential value tied to VillageMD businesses. The acquisition aims to combine retail and healthcare expertise, positioning WBA for a strategic turnaround.2

Hims & Hers Health shares rose 4.29% following an FDA decision allowing continued production of semaglutide-based weight-loss drugs under specific guidelines. This development bolsters the company’s revenue potential, with semaglutide products expected to drive a significant portion of its $725 million weight-loss revenue forecast.3